Goss Christopher H, Quittner Alexandra L
Department of Medicine, University of Washington Medical Center, Seattle, Washington 98195, USA.
Proc Am Thorac Soc. 2007 Aug 1;4(4):378-86. doi: 10.1513/pats.200703-039BR.
Over the past 20 years, there has been tremendous progress in the area of patient-reported outcomes (PROs). A PRO instrument is defined as any measure of a patient's health status that is elicited directly from the patient and assesses how the patient "feels or functions with respect to his or her health condition." The advances seen in clinical research regarding PROs has been mirrored in research in cystic fibrosis (CF). A large number of instruments have been used for both therapeutic and nontherapeutic clinical research for many chronic conditions. This review will summarize a history of the development of PROs and how PROs are viewed by the U.S. Food and Drug Administration. We will then review the current state of the art of patient-reported outcomes in CF, specifically addressing the evaluation of different PRO instruments in terms of their reliability and validity. Finally, we will delineate further areas for development of PROs in CF. We believe that the future of CF research will incorporate a more diverse selection of PRO outcome measures; these outcome measures ultimately may be incorporated into clinical care to standardize symptom assessment and provide information regarding the need for specific clinical interventions to improve the quality of care delivered to these patients.
在过去20年里,患者报告结局(PROs)领域取得了巨大进展。PRO工具被定义为任何直接从患者那里获取的、评估患者“在其健康状况方面的感受或功能”的患者健康状况衡量指标。临床研究中在PROs方面取得的进展在囊性纤维化(CF)研究中也有所体现。大量工具已被用于许多慢性病的治疗性和非治疗性临床研究。本综述将总结PROs的发展历程以及美国食品药品监督管理局对PROs的看法。然后,我们将回顾CF中患者报告结局的当前技术水平,特别从可靠性和有效性方面探讨不同PRO工具的评估情况。最后,我们将勾勒出CF中PROs进一步的发展领域。我们相信,CF研究的未来将纳入更多样化的PRO结局指标选择;这些结局指标最终可能会被纳入临床护理,以规范症状评估,并提供有关是否需要特定临床干预措施以提高为这些患者提供的护理质量的信息。